Media coverage about Antares Pharma (NASDAQ:ATRS) has trended positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Antares Pharma earned a daily sentiment score of 0.32 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.7341375703336 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of equities research analysts have recently issued reports on the company. BidaskClub lowered Antares Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright set a $4.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Tuesday, March 27th. Finally, ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $3.94.
Shares of ATRS stock traded up $0.05 during trading hours on Thursday, reaching $2.14. The company had a trading volume of 1,710,049 shares, compared to its average volume of 1,392,676. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.94 and a current ratio of 3.53. The firm has a market cap of $321.42, a P/E ratio of -19.45 and a beta of 0.21.
WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/05/favorable-media-coverage-somewhat-unlikely-to-impact-antares-pharma-atrs-stock-price-2/2027700.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.